risedronic acid has been researched along with Hangman Fracture in 105 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 9.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "This study assessed the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs) (bazedoxifene, raloxifene) and placebo for the treatment of osteoporosis in hormone-sensitive cancer patients receiving endocrine therapy (men with prostate cancer [MPC] on hormone ablation therapy [HAT], and women with breast cancer [WBC] on adjuvant aromatase inhibitor therapy [AAIT])." | 5.41 | The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW)." | 5.41 | The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 5.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "Minodronate has better clinical efficacy in the treatment of osteoporosis than other drugs (alendronate, risedronate, raloxifene, or eldecalcitol)." | 5.05 | Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis. ( Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z, 2020) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| " In addition, we looked at benefit and harm comparisons between different dosage regimens for risedronate and between risedronate and other anti-osteoporotic drugs." | 2.82 | Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. ( Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022) |
| " We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients." | 2.79 | Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. ( Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014) |
| " Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and adverse events (AEs) were evaluated." | 2.79 | Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. ( Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014) |
| " This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis." | 2.78 | A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. ( Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013) |
| "The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis." | 2.71 | Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. ( Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004) |
| " Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events." | 2.69 | Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. ( Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000) |
| " In these studies another formulation of the drug and other dosing instructions are used." | 2.68 | A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. ( Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997) |
| "Male osteoporosis is an important public health issue and remains undertreated." | 2.45 | Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. ( Chen, JT; Zhong, ZM, 2009) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported." | 2.42 | [Bone quality in treatment with raroxifene ]. ( Nakamura, T, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111)." | 1.51 | Predictive and modifying factors of bone mineral density decline in patients with COPD. ( Asano, K; Betsuyaku, T; Chubachi, S; Fukunaga, K; Irie, H; Kameyama, N; Nakamura, H; Sakurai, K; Sasaki, M; Sayama, K; Tsutsumi, A, 2019) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.90) | 18.2507 |
| 2000's | 66 (62.86) | 29.6817 |
| 2010's | 28 (26.67) | 24.3611 |
| 2020's | 9 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, J | 1 |
| Ke, Z | 1 |
| Dong, S | 1 |
| Lv, M | 1 |
| Yuan, Y | 1 |
| Song, L | 1 |
| Wu, K | 1 |
| Xu, K | 1 |
| Hu, Y | 1 |
| Wells, GA | 1 |
| Hsieh, SC | 1 |
| Zheng, C | 1 |
| Peterson, J | 2 |
| Tugwell, P | 3 |
| Liu, W | 1 |
| Li, P | 1 |
| Wu, X | 1 |
| Li, Y | 1 |
| Huang, J | 1 |
| Tutaworn, T | 1 |
| Nieves, JW | 1 |
| Wang, Z | 1 |
| Levin, JE | 1 |
| Yoo, JE | 1 |
| Lane, JM | 1 |
| Nicolopoulos, K | 2 |
| Moshi, MR | 2 |
| Stringer, D | 2 |
| Ma, N | 2 |
| Jenal, M | 2 |
| Vreugdenburg, T | 2 |
| Soen, S | 3 |
| Kishimoto, H | 6 |
| Hagino, H | 5 |
| Sone, T | 1 |
| Ohishi, H | 2 |
| Fujimoto, T | 1 |
| Sasaki, E | 1 |
| Tanaka, S | 3 |
| Sugimoto, T | 2 |
| Kendler, DL | 3 |
| Marin, F | 3 |
| Geusens, P | 3 |
| López-Romero, P | 2 |
| Lespessailles, E | 2 |
| Body, JJ | 2 |
| Minisola, S | 3 |
| Liu, Q | 1 |
| Chen, D | 1 |
| Ye, Z | 1 |
| Jin, Z | 1 |
| Ma, T | 1 |
| Huang, X | 1 |
| Albert, SG | 1 |
| Reddy, S | 1 |
| Russo, LA | 1 |
| Zerbini, CA | 1 |
| Greenspan, SL | 2 |
| Bagur, A | 1 |
| Stepan, JJ | 1 |
| Lakatos, P | 1 |
| Casado, E | 1 |
| Moericke, R | 1 |
| Fahrleitner-Pammer, A | 1 |
| Kameyama, N | 1 |
| Chubachi, S | 1 |
| Sasaki, M | 1 |
| Tsutsumi, A | 1 |
| Irie, H | 1 |
| Sakurai, K | 1 |
| Sayama, K | 1 |
| Nakamura, H | 1 |
| Asano, K | 1 |
| Betsuyaku, T | 1 |
| Fukunaga, K | 1 |
| Nakamura, T | 7 |
| Nakano, T | 2 |
| Ito, M | 2 |
| Hashimoto, J | 3 |
| Tobinai, M | 3 |
| Mizunuma, H | 1 |
| Miyazaki, T | 2 |
| Uemura, Y | 1 |
| Kuroda, T | 1 |
| Miyakawa, N | 1 |
| Fukunaga, M | 4 |
| Ohashi, Y | 3 |
| Ohta, H | 1 |
| Mori, S | 1 |
| Hosoi, T | 1 |
| Itoi, E | 1 |
| Orimo, H | 3 |
| Shiraki, M | 5 |
| Kasukawa, Y | 1 |
| Miyakoshi, N | 1 |
| Ebina, T | 1 |
| Aizawa, T | 1 |
| Hongo, M | 1 |
| Nozaka, K | 1 |
| Ishikawa, Y | 1 |
| Saito, H | 1 |
| Chida, S | 1 |
| Shimada, Y | 1 |
| Horii, S | 1 |
| Messori, A | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Marinai, C | 1 |
| Reid, IR | 1 |
| Yamamoto, M | 1 |
| Yoshida, S | 2 |
| Keating, GM | 1 |
| Umemura, T | 1 |
| Ando, T | 1 |
| Kamisaki, T | 1 |
| Nishikawa, M | 1 |
| Muraoka, R | 2 |
| Ikeda, Y | 1 |
| Takeda, K | 1 |
| Osawa, M | 1 |
| Mawatari, T | 1 |
| Iwamoto, Y | 1 |
| Bell, JM | 1 |
| Shields, MD | 1 |
| Watters, J | 1 |
| Hamilton, A | 1 |
| Beringer, T | 1 |
| Elliott, M | 1 |
| Quinlivan, R | 1 |
| Tirupathi, S | 1 |
| Blackwood, B | 1 |
| Imai, T | 1 |
| Kawakami, K | 1 |
| Nayak, S | 1 |
| Lems, WF | 1 |
| Geusens, PP | 1 |
| Hochberg, MC | 1 |
| Curtis, JR | 1 |
| Westfall, AO | 1 |
| Cheng, H | 1 |
| Saag, KG | 2 |
| Delzell, E | 1 |
| Zhong, ZM | 1 |
| Chen, JT | 1 |
| Wasserfallen, JB | 1 |
| Krieg, MA | 1 |
| Greiner, RA | 1 |
| Lamy, O | 1 |
| Ohtori, S | 1 |
| Akazawa, T | 1 |
| Murata, Y | 1 |
| Kinoshita, T | 1 |
| Yamashita, M | 1 |
| Nakagawa, K | 1 |
| Inoue, G | 1 |
| Nakamura, J | 1 |
| Orita, S | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Eguchi, Y | 1 |
| Yamauchi, K | 1 |
| Suzuki, M | 1 |
| Aoki, Y | 1 |
| Takahashi, K | 1 |
| Roux, C | 4 |
| Goldstein, JL | 1 |
| Zhou, X | 2 |
| Klemes, A | 1 |
| Lindsay, R | 3 |
| El Rachkidi, R | 1 |
| Sari-Leret, ML | 1 |
| Wolff, S | 1 |
| Guadalix, S | 1 |
| Martínez-Díaz-Guerra, G | 1 |
| Lora, D | 1 |
| Vargas, C | 1 |
| Gómez-Juaristi, M | 1 |
| Cobaleda, B | 1 |
| González, EM | 1 |
| Hawkins, F | 2 |
| Lee, JH | 1 |
| Lee, SH | 1 |
| Eastell, R | 5 |
| Hannon, RA | 1 |
| Wenderoth, D | 1 |
| Rodriguez-Moreno, J | 1 |
| Sawicki, A | 1 |
| Hadji, P | 1 |
| Zanchetta, JR | 2 |
| Russo, L | 1 |
| Recknor, CP | 1 |
| McKiernan, FE | 1 |
| Silverman, SL | 1 |
| Alam, J | 1 |
| Burge, RT | 1 |
| Krege, JH | 1 |
| Lakshmanan, MC | 1 |
| Masica, DN | 1 |
| Mitlak, BH | 1 |
| Stock, JL | 1 |
| Davey, DA | 1 |
| McClung, MR | 4 |
| Benhamou, CL | 1 |
| Man, Z | 1 |
| Tlustochowicz, W | 1 |
| Eusebio, R | 1 |
| Balske, AM | 1 |
| Matzkin, E | 1 |
| Olszynski, WP | 2 |
| Recker, R | 1 |
| Delmas, PD | 1 |
| Glüer, CC | 1 |
| Ringe, JD | 2 |
| Möricke, R | 1 |
| Papaioannu, N | 1 |
| Farahmand, P | 1 |
| Martínez, G | 1 |
| Nolla, JM | 1 |
| Niedhart, C | 1 |
| Guañabens, N | 1 |
| Nuti, R | 1 |
| Martín-Mola, E | 1 |
| Thomasius, F | 1 |
| Kapetanos, G | 1 |
| Peña, J | 1 |
| Graeff, C | 1 |
| Petto, H | 1 |
| Sanz, B | 1 |
| Reisinger, A | 1 |
| Zysset, PK | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Kushida, K | 2 |
| Taketani, Y | 1 |
| Minaguchi, H | 1 |
| Inoue, T | 2 |
| Morita, R | 1 |
| Morii, H | 2 |
| Yamamoto, K | 2 |
| Baranauskaite, A | 1 |
| Eriksen, EF | 2 |
| Melsen, F | 1 |
| Sod, E | 1 |
| Barton, I | 4 |
| Chines, A | 2 |
| Minne, HW | 2 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Deal, CL | 1 |
| Miller, PD | 2 |
| Watts, NB | 7 |
| Josse, RG | 1 |
| Hamdy, RC | 1 |
| Hughes, RA | 3 |
| Manhart, MD | 2 |
| Calligeros, D | 1 |
| Felsenberg, D | 2 |
| Ettinger, MP | 1 |
| Cranney, A | 2 |
| Waldegger, L | 1 |
| Zytaruk, N | 1 |
| Shea, B | 2 |
| Weaver, B | 1 |
| Papaioannou, A | 1 |
| Robinson, V | 2 |
| Wells, G | 2 |
| Adachi, JD | 5 |
| Guyatt, G | 1 |
| Seibel, MJ | 1 |
| Naganathan, V | 1 |
| Grauer, A | 2 |
| Seeman, E | 1 |
| Adachi, J | 1 |
| Jackson, RD | 1 |
| Songcharoen, S | 1 |
| Rizzoli, R | 2 |
| Di Munno, O | 1 |
| Horlait, S | 1 |
| Valent, D | 1 |
| Harris, ST | 2 |
| Li, Z | 4 |
| Chines, AA | 4 |
| Hanley, DA | 2 |
| Brown, JP | 2 |
| Kanis, JA | 3 |
| Borgstrom, F | 2 |
| Johnell, O | 3 |
| Jonsson, B | 2 |
| Itabashi, A | 1 |
| Kaneda, K | 1 |
| Nawata, H | 1 |
| Cooper, C | 1 |
| Barton, IP | 3 |
| van Staa, TP | 1 |
| Mellström, DD | 1 |
| Sörensen, OH | 2 |
| Goemaere, S | 1 |
| Johnson, TD | 1 |
| Boonen, S | 3 |
| El-Hajj Fuleihan, G | 1 |
| Delmas, P | 1 |
| Bartl, R | 1 |
| Palomba, S | 1 |
| Orio, F | 1 |
| Manguso, F | 1 |
| Falbo, A | 1 |
| Russo, T | 1 |
| Tolino, A | 1 |
| Tauchmanovà, L | 1 |
| Colao, A | 1 |
| Doldo, P | 1 |
| Mastrantonio, P | 1 |
| Zullo, F | 1 |
| Meredith, MP | 2 |
| Chesnut, CH | 2 |
| White, NJ | 1 |
| Perry, CM | 1 |
| Poole, KE | 1 |
| Warburton, EA | 1 |
| Reeve, J | 1 |
| Carlsson, A | 1 |
| Sintonen, H | 1 |
| Haentjens, P | 1 |
| Burge, R | 1 |
| Muschitz, C | 1 |
| Roschger, P | 1 |
| Patsch, J | 1 |
| Pollhammer, I | 1 |
| Koller, B | 1 |
| Klaushofer, K | 1 |
| Resch, H | 1 |
| McKeever, CD | 2 |
| Boucher, M | 1 |
| Coyle, D | 1 |
| Gärtner, R | 1 |
| Clemmesen, B | 1 |
| Ravn, P | 1 |
| Zegels, B | 1 |
| Taquet, AN | 1 |
| Christiansen, C | 1 |
| Reginster, JY | 1 |
| Genant, HK | 1 |
| Hangartner, T | 1 |
| Keller, M | 1 |
| Brown, J | 2 |
| Hoseyni, MS | 2 |
| Axelrod, DW | 1 |
| Reginster, J | 1 |
| Hooper, M | 1 |
| Brandi, ML | 1 |
| Lund, B | 1 |
| Ethgen, D | 1 |
| Pack, S | 1 |
| Roumagnac, I | 1 |
| Reid, DM | 3 |
| Laan, RF | 2 |
| Sacco-Gibson, NA | 1 |
| Wenderoth, DH | 1 |
| Adami, S | 2 |
| Eusebio, RA | 1 |
| Devogelaer, JP | 2 |
| Wallach, S | 1 |
| Cohen, S | 1 |
| Hosking, DJ | 1 |
| Doherty, SM | 1 |
| Maricic, M | 1 |
| Rosen, C | 1 |
| Papapoulos, SE | 1 |
| Compston, JE | 1 |
| Netelenbos, JC | 1 |
| Kruse, HP | 1 |
| McClung, M | 1 |
| Hodsman, AB | 1 |
| Josse, R | 1 |
| Emkey, RD | 1 |
| Bolognese, MA | 1 |
| Balske, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures[NCT01709110] | Phase 4 | 1,366 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men[NCT00503399] | Phase 3 | 92 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 18 |
| Risedronate | 31 |
Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 26 |
| Risedronate | 63 |
(NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 2 |
| Risedronate | 12 |
"The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation.~A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 28 |
| Risedronate | 64 |
A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 25 |
| Risedronate | 38 |
"A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture.~All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 30 |
| Risedronate | 61 |
Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 40 |
| Risedronate | 57 |
Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as ~20 to 25% (mild), ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 31 |
| Risedronate | 69 |
Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 4.5 | 3.4 |
| Teriparatide | 4.5 | 3.4 |
(NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | Centimeter (cm) (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 155.0 | 154.5 |
| Teriparatide | 154.7 | 154.3 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.62 | 0.68 |
| Teriparatide | 0.59 | 0.65 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.72 | 0.76 |
| Teriparatide | 0.70 | 0.74 |
Least Squares (LS) Means were adjusted for age, baseline propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 4.31 |
| Risedronate | 2.52 |
Least Squares (LS) Means were adjusted for age, baseline serum aminoterminal propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 12.28 |
| Risedronate | 2.94 |
Anterior bending and axial torsion were measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton/millimeter/radian (N/mm/rad) (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anterior bending stiffness at 6 months | Anterior bending stiffness at 18 months | Axial torsion stiffness at 6 months | Axial torsion stiffness at 18 months | Anterior bending strength at 6 months | Anterior bending strength at 18 months | Axial torsion strength at 6 months | Axial torsion strength at 18 months | |
| Risedronate | 415705.0 | 233283.0 | 77830.7 | 56639.3 | 8827.2 | 4822.0 | 3664.0 | 2545.8 |
| Teriparatide | 664969.0 | 1209225.0 | 142902.9 | 279392.8 | 12490.9 | 26046.4 | 6127.7 | 14181.3 |
Dual x-ray absorptiometry (DXA) techniques validated this measurement at skeletal sites that are at risk of osteoporotic fracture, such as lumbar spine, femoral neck, and hip. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | grams per square centimeter (g/cm^2) (Mean) | ||
|---|---|---|---|
| Lumbar spine (n=38; n=39) | Hip (n=38; n=37) | Femoral neck (n=38; n=37) | |
| Risedronate | 0.037 | 0.007 | -0.007 |
| Teriparatide | 0.068 | 0.014 | 0.014 |
Axial compression was measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated the strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton per millimeter (N/mm) (Least Squares Mean) | |||
|---|---|---|---|---|
| Axial compression stiffness at 6 months | Axial compression stiffness at 18 months | Axial compression strength at 6 months | Axial compression strength at 18 months | |
| Risedronate | 407.6 | 363.7 | 313.6 | 209.4 |
| Teriparatide | 890.7 | 1973.9 | 580.7 | 1287.5 |
Three-dimensional (3-D) microstructure variables of T12 were assessed by HR-QCT. In contrast with regular QCT that assessed 3 millimeter (mm) slide thickness, HR-QCT used segmentation of 1 single vertebra with approximately 100 consecutive slides reconstructed at 300-400 micrometer (µm) slice increments covering the complete vertebral body. Least Squares (LS) Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) | |||
|---|---|---|---|---|
| Integral BMD at 6 months | Integral BMD at 18 months | Trabecular BMD at 6 months | Trabecular BMD at 18 months | |
| Risedronate | -1.91 | 0.68 | -0.87 | 0.22 |
| Teriparatide | -0.42 | 10.72 | -0.70 | 9.53 |
P1NP was used as a serum biochemical marker of collagen synthesis, reflecting the formation of new osteoid. (NCT00503399)
Timeframe: Baseline, 3 months, 6 months, 18 months
| Intervention | micrograms per deciliter (μg/dL) (Least Squares Mean) | ||
|---|---|---|---|
| P1NP at 3 months | P1NP at 6 months | P1NP at 18 months | |
| Risedronate | -16.09 | -16.50 | -15.58 |
| Teriparatide | 27.33 | 52.55 | 28.48 |
β-CTx was used as a biochemical marker of bone turnover/resorption, reflecting collagen breakdown of the bone matrix. (NCT00503399)
Timeframe: 3, 6, 18 months
| Intervention | nanograms per deciliter (ng/dL) (Least Squares Mean) | ||
|---|---|---|---|
| β-CTx at 3 months | β-CTx at 6 months | β-CTx at 18 months | |
| Risedronate | -0.15 | -0.14 | -0.11 |
| Teriparatide | 0.12 | 0.25 | 0.03 |
Summary tables of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module. Fractures that occurred during the study were collected separately as an additional safety variable. The number of participants experiencing hypercalcemia was summarized for each treatment arm. Hypercalcemia was defined as a serum calcium level corrected for albumin of >2.7 millimole per liter (mmol/L) (10.8 milligram per deciliter [mg/dL]). (NCT00503399)
Timeframe: Baseline up to 18 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Serious Adverse Events (SAEs) | Other Non-serious AEs | Fractures | Hypercalcemia | |
| Risedronate | 22 | 30 | 5 | 0 |
| Teriparatide | 13 | 22 | 0 | 0 |
35 reviews available for risedronic acid and Hangman Fracture
| Article | Year |
|---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Netw | 2022 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Aged; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractu | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; M | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Horm | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Huma | 2023 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-C | 2020 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Dru | 2017 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp | 2014 |
Ibandronate: A Review in Japanese Patients with Osteoporosis.
Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; D | 2016 |
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Topics: Adult; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III | 2017 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; | 2017 |
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Denosumab; Humans; Male; Osteoporosis; Os | 2017 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow | 2009 |
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem | 2012 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Osteoporosis: diagnosis and treatment of vertebral fractures].
Topics: Age Factors; Aged; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle A | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Editorial: greater risk, greater benefit--true or false?
Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi | 2003 |
[Risedronate treatment for osteoporosis].
Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra | 2004 |
[VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].
Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteo | 2004 |
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Ac | 2004 |
[Bone quality in treatment with raroxifene ].
Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis | 2004 |
Risedronate once a week.
Topics: Bone Density; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Humans | 2003 |
[Evidence of risedronate for treatment of osteoporosis].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Evidenc | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os | 2008 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos | 2001 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; H | 2002 |
Bone quality: getting closer to a definition.
Topics: Animals; Bone Density; Etidronic Acid; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Risedron | 2002 |
36 trials available for risedronic acid and Hangman Fracture
| Article | Year |
|---|---|
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dou | 2020 |
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Osteop | 2020 |
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Topics: Aged; Double-Blind Method; Female; Humans; Osteoporosis; Postmenopause; Risedronic Acid; Risk Factor | 2018 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; E | 2013 |
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glome | 2014 |
Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Incidence; Ost | 2014 |
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relati | 2014 |
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; | 2016 |
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; | 2017 |
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Therapy, | 2017 |
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation | 2010 |
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cholecalciferol; Et | 2011 |
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid | 2012 |
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Admi | 2013 |
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Euro | 2013 |
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid | 2002 |
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Incidence; Osteoporosis, Postmenopau | 2003 |
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo | 2004 |
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Humans; Lumbar Verteb | 2004 |
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Height; Bone and Bones; Collagen; Collagen | 2004 |
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic | 2004 |
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; | 2004 |
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Calcium Channel Blockers; Double-Blind Method; Etidronic A | 2004 |
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Topics: Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Etidronic Acid; Fema | 2005 |
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; I | 2005 |
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
Topics: Bone Density; Double-Blind Method; Etidronic Acid; Humans; Meta-Analysis as Topic; Osteoporosis, Pos | 2005 |
Fracture risk remains reduced one year after discontinuation of risedronate.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Collag | 2008 |
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Double-Blind Method | 1997 |
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Fema | 1999 |
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Australia; Bone Density; Calcium Channe | 2000 |
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density; Consumer Product | 2000 |
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Ca | 2000 |
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2001 |
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos | 2002 |
35 other studies available for risedronic acid and Hangman Fracture
| Article | Year |
|---|---|
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Di | 2023 |
Predictive and modifying factors of bone mineral density decline in patients with COPD.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Female; Humans | 2019 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Drug Administra | 2017 |
Osteoporosis in men.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteoporosis; | 2008 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr | 2008 |
[Osteoporosis management in general practice. Preventing spontaneous bone fractures].
Topics: Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Fractures, Spo | 2010 |
Atypical bilateral pedicle fracture in long-term bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Low Back Pain; Lumbar Verteb | 2011 |
Multiple vertebral compression fractures associated with post partum osteoporosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fractures, C | 2011 |
Effect of stopping risedronate after long-term treatment on bone turnover.
Topics: Aged; Bone Density; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Lumbar V | 2011 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
[Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it].
Topics: Bone Density; Diphosphonates; Double-Blind Method; Etidronic Acid; Family Practice; Female; Follow-U | 2003 |
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].
Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteop | 2003 |
[To treat effectively without delay. The data on fractures decisive].
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dipho | 2003 |
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].
Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans | 2003 |
Efficacy of risedronate on clinical vertebral fractures within six months.
Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; R | 2004 |
[Consistent therapeutic success in osteoporosis].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip F | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidr | 2005 |
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Health Care Costs; Huma | 2006 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.
Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density | 2007 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2001 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop | 2001 |
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
Topics: Biometry; Endpoint Determination; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Rand | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |